, Volume 26, Issue 3, pp 103-110

First online:

Human Umbilical Vein Endothelial Cells Express Complement Receptor 1 (CD35) and Complement Receptor 4 (CD11c/CD18) in vitro

  • Harald LangeggenAffiliated withUllevål Hospital, University of OsloDepartment of Pediatric Surgery, Ullevål Hospital, University of Oslo
  • , Knut Erik BergeAffiliated withInstitute of Medical Genetics, Ullevål Hospital, University of Oslo
  • , Egil JohnsonAffiliated withUllevål Hospital, University of OsloDepartment of Gastroenterological Surgery, Ullevål Hospital, University of Oslo
  • , Geir HetlandAffiliated withDepartment of Environmental Medicine, National Institute of Public Health

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


We have examined complement receptors on human umbilical vein endothelial cells (HUVEC) and found that they express complement receptor 1 (CR1, CD35) and complement receptor 4 (CR4, CD11c/CD18), but not complement receptor 3 (CR3, CD11b/CD18). Binding of monoclonal antibodies against CR1 (CD35) and CR4 (CD11c/CD18) to HUVEC was demonstrated by flow cytometry. The presence of the corresponding mRNAs was confirmed by reverse transcriptase-polymerase chain reaction (RT-PCR) and sequencing of the amplified cDNA fragments. When HUVEC were treated with inflammatory mediators, chemotactic agents or the secretagogue phorbol-12-myristate-13-acetate (PMA), no change in reactivity to CR1 (CD35) or CR4 (CD11c/CD18) monoclonal antibodies was detected on the surface of the cells compared with untreated cells. The presence of CR1 (CD35) and CR4 (CD11c/CD18) on HUVEC indicates that endothelial cells (EC) have the potential to bind C3b and iC3b, respectively, which both mediate biological effects in the course of complement activation.

CR1 (CD35) CR4 (CD11c/CD18) endothelial cells